utah medical products, inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. for more information about utah medical products, inc., visit utmd’s website at www.utahmed.com.
Company profile
Ticker
UTMD
Exchange
Website
CEO
Kevin Cornwell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Utah Medical Products Ltd. • Columbia Medical & Surgical, Inc. • Femcare Group Limited • Femcare Limited • Femcare Australia Pty Ltd • Femcare N.Z. Ltd • Utah Medical Products Canada Inc. ...
IRS number
870342734
UTMD stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance
30 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Utah Medical Products, Inc. Increases Regular Quarterly Dividend
31 Oct 23
8-K
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023
26 Oct 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023
25 Jul 23
S-8
Registration of securities for employees
14 Jul 23
Latest ownership filings
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
Brian Koopman
26 Dec 23
4
Brian Koopman
20 Jun 23
144
Notice of proposed sale of securities
14 Jun 23
4
PAUL O RICHINS
19 May 23
144
Notice of proposed sale of securities
18 May 23
4
PAUL O RICHINS
17 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
71.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 89 |
Opened positions | 7 |
Closed positions | 2 |
Increased positions | 32 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 234.71 bn |
Total shares | 2.55 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FMR | 382.09 k | $35.61 bn |
T. Rowe Price Investment Management | 341.12 k | $31.84 bn |
Renaissance Technologies | 203.39 k | $18.98 bn |
BLK Blackrock | 196.61 k | $18.32 bn |
Vanguard | 167.55 k | $15.62 bn |
Dimensional Fund Advisors | 155.13 k | $14.46 bn |
Rice Hall James & Associates | 113.00 k | $10.53 bn |
Ranger Investment Management | 78.68 k | $7.33 bn |
STT State Street | 70.92 k | $6.63 bn |
Russell Investments | 67.67 k | $6.31 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Oct 23 | Brian Koopman | Employee Stock Option - Right to Buy Common Stock | Grant | Acquire A | No | No | 77.07 | 500 | 38.54 k | 4,600 |
15 Jun 23 | Brian Koopman | Common Stock | Gift | Dispose G | No | No | 94.31 | 60 | 5.66 k | 932 |
18 May 23 | Richins Paul O | Common Stock | Sell | Dispose S | Yes | No | 93.47 | 700 | 65.43 k | 21,461 |
17 Mar 23 | Richins Paul O | Common Stock | Gift | Dispose G | Yes | No | 92.5 | 150 | 13.88 k | 22,161 |
8 Feb 23 | Payne Barbara A | Common Stock | Gift | Dispose G | No | No | 89.9974 | 500 | 45.00 k | 4,838 |